Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study.

Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A.

Lancet. 2007 Nov 24;370(9601):1757-63.

PMID:
18037080
2.

Systemic rotavirus infection.

Ramig RF.

Expert Rev Anti Infect Ther. 2007 Aug;5(4):591-612. Review.

PMID:
17678424
3.

Rotavirus vaccines: recent developments and future considerations.

Angel J, Franco MA, Greenberg HB.

Nat Rev Microbiol. 2007 Jul;5(7):529-39. Review.

PMID:
17571094
4.

Rotavirus antigenemia in children is associated with viremia.

Blutt SE, Matson DO, Crawford SE, Staat MA, Azimi P, Bennett BL, Piedra PA, Conner ME.

PLoS Med. 2007 Apr;4(4):e121.

5.

Postmarketing monitoring of intussusception after RotaTeq vaccination--United States, February 1, 2006-February 15, 2007.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2007 Mar 16;56(10):218-22.

6.

Hospitalizations and deaths from diarrhea and rotavirus among children <5 years of age in the United States, 1993-2003.

Fischer TK, Viboud C, Parashar U, Malek M, Steiner C, Glass R, Simonsen L.

J Infect Dis. 2007 Apr 15;195(8):1117-25. Epub 2007 Mar 6.

PMID:
17357047
7.

Neonatal infection with G10P[11] rotavirus did not confer protection against subsequent rotavirus infection in a community cohort in Vellore, South India.

Banerjee I, Gladstone BP, Le Fevre AM, Ramani S, Iturriza-Gomara M, Gray JJ, Brown DW, Estes MK, Muliyil JP, Jaffar S, Kang G.

J Infect Dis. 2007 Mar 1;195(5):625-32. Epub 2007 Jan 22.

8.

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.

Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM; Pentavalent Rotavirus Vaccine Dose Confirmation Efficacy Study Group.

Pediatrics. 2007 Jan;119(1):11-8.

PMID:
17200266
9.

Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Parashar UD, Alexander JP, Glass RI; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2006 Aug 11;55(RR-12):1-13.

10.

Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.

Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ.

J Infect Dis. 2006 Aug 1;194(3):370-6. Epub 2006 Jun 23.

PMID:
16826486
11.

Rotavirus serotype G9 is associated with more-severe disease in Latin America.

Linhares AC, Verstraeten T, Wolleswinkel-van den Bosch J, Clemens R, Breuer T.

Clin Infect Dis. 2006 Aug 1;43(3):312-4. Epub 2006 Jun 23.

PMID:
16804845
12.

Rotavirus and rotavirus vaccines.

Glass RI, Bresee J, Jiang B, Parashar U, Yee E, Gentsch J.

Adv Exp Med Biol. 2006;582:45-54. Review.

PMID:
16802618
13.

Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000.

Malek MA, Curns AT, Holman RC, Fischer TK, Bresee JS, Glass RI, Steiner CA, Parashar UD.

Pediatrics. 2006 Jun;117(6):1887-92.

PMID:
16740827
14.

Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial.

Bhandari N, Sharma P, Glass RI, Ray P, Greenberg H, Taneja S, Saksena M, Rao CD, Gentsch JR, Parashar U, Maldonado Y, Ward RL, Bhan MK.

Vaccine. 2006 Jul 26;24(31-32):5817-23. Epub 2006 May 12.

PMID:
16735085
15.

Temporal and geographic trends of rotavirus activity in the United States, 1997-2004.

Turcios RM, Curns AT, Holman RC, Pandya-Smith I, LaMonte A, Bresee JS, Glass RI; National Respiratory and Enteric Virus Surveillance System Collaborating Laboratories.

Pediatr Infect Dis J. 2006 May;25(5):451-4.

PMID:
16645512
16.

Viremia and clinical manifestations in children with rotavirus infection.

Chiappini E, Galli L, de Martino M.

J Infect Dis. 2006 May 1;193(9):1333. No abstract available.

PMID:
16586374
17.

Rotavirus and severe childhood diarrhea.

Parashar UD, Gibson CJ, Bresee JS, Glass RI.

Emerg Infect Dis. 2006 Feb;12(2):304-6.

18.

RotaTeq: a pentavalent bovine--human reassortant rotavirus vaccine.

Offit PA, Clark HF.

Pediatr Ann. 2006 Jan;35(1):29-34. Review. No abstract available.

PMID:
16466073
19.

Immunity and correlates of protection for rotavirus vaccines.

Franco MA, Angel J, Greenberg HB.

Vaccine. 2006 Apr 5;24(15):2718-31. Epub 2006 Jan 17. Review.

PMID:
16446014
20.

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM; Rotavirus Efficacy and Safety Trial (REST) Study Team.

N Engl J Med. 2006 Jan 5;354(1):23-33.

Supplemental Content

Support Center